Needham analyst Michael Matson has maintained their neutral stance on ZBH stock, giving a Hold rating today.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Michael Matson has given his Hold rating due to a combination of factors affecting Zimmer Biomet Holdings. The company’s third-quarter revenue for 2025 slightly missed market expectations, although its earnings per share (EPS) did manage to surpass forecasts. Despite this, management decided to maintain its revenue and EPS guidance for the year, although they adjusted their expectations for organic constant currency revenue growth.
Matson noted that while there was an improvement in constant currency organic revenue growth from the previous quarter, it did not meet management’s expectations, primarily due to slower growth in emerging markets and restorative therapies. Additionally, Zimmer Biomet experienced a slight decline in its market share for knee and hip reconstructions. With only modest EPS growth anticipated through 2026, partly due to factors such as the dilution from Paragon 28 and tariffs, Matson believes a Hold rating is appropriate.
In another report released today, TD Cowen also maintained a Hold rating on the stock with a $99.00 price target.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZBH in relation to earlier this year.